 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
1 term
|
 |
|
Biological process
|
immune response
|
1 term
|
 |
|
Biochemical function
|
chemokine activity
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
276:4909-4916
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Solution structure and dynamics of myeloid progenitor inhibitory factor-1 (MPIF-1), a novel monomeric CC chemokine.
|
|
K.Rajarathnam,
Y.Li,
T.Rohrer,
R.Gentz.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
MPIF-1, a CC chemokine, is a specific inhibitor of myeloid progenitor cells and
is the most potent activator of monocytes. The solution structure of myeloid
progenitor inhibitor factor-1 (MPIF-1) has been determined by NMR spectroscopy.
The structure reveals that MPIF-1 is a monomer with a well defined core except
for termini residues and adopts the chemokine fold of three beta-strands and an
overlying alpha-helix. In addition to the four cysteines that characterize most
chemokines, MPIF-1 has two additional cysteines that form a disulfide bond. The
backbone dynamics indicate that the disulfide bonds and the adjacent residues
that include the functionally important N-terminal and N-terminal loop residues
show significant dynamics. MPIF-1 is a highly basic protein (pI >9), and the
structure reveals distinct positively charged pockets that could be correlated
to proteoglycan binding. MPIF-1 is processed from a longer proprotein at the N
terminus and the latter is also functional though with reduced potency, and both
proteins exist as monomers under a variety of solution conditions. MPIF-1 is
therefore unique because longer proproteins of all other chemokines oligomerize
in solution. The MPIF-1 structure should serve as a template for future
functional studies that could lead to therapeutics for preventing
chemotherapy-associated myelotoxicity.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. A, superposition of the 30 simulated annealing
structures about the average structure. B, the same as in panel
A except the N-terminal (1-10) and the C-terminal (67) residues
have been omitted for clarity. C, a schematic representation of
MPIF-1 in the same orientation as shown in panel B created using
the program MOLMOL (52).
|
 |
Figure 6.
Fig. 6. Surface charge distribution of MPIF-1 (A), MPIF-1
after rotating 180° (B), IL-8 (C), and MIP-1 (D) created
using the program MOLMOL (52). The orientation is essentially
the same as shown in Fig. 4. Positive and negatively charged
regions are shown in blue and red, respectively.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2001,
276,
4909-4916)
copyright 2001.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
H.Nomiyama,
N.Osada,
and
O.Yoshie
(2010).
The evolution of mammalian chemokine genes.
|
| |
Cytokine Growth Factor Rev, 21,
253-262.
|
 |
|
|
|
|
 |
K.Umezawa,
J.Ikebe,
M.Nomizu,
H.Nakamura,
and
J.Higo
(2009).
Conformational requirement on peptides to exert laminin's activities and search for protein segments with laminin's activities.
|
| |
Biopolymers, 92,
124-131.
|
 |
|
|
|
|
 |
E.J.Fernandez,
and
E.Lolis
(2002).
Structure, function, and inhibition of chemokines.
|
| |
Annu Rev Pharmacol Toxicol, 42,
469-499.
|
 |
|
|
|
|
 |
B.T.Seet,
R.Singh,
C.Paavola,
E.K.Lau,
T.M.Handel,
and
G.McFadden
(2001).
Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor.
|
| |
Proc Natl Acad Sci U S A, 98,
9008-9013.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
|